Can prestin level be a biomarker for determining sensorineural hearing loss?

dc.contributor.authorEmre, Sadettin
dc.contributor.authorKarlidag, Turgut
dc.contributor.authorAydinb, Sueleyman
dc.contributor.authorKaygusuz, Irfan
dc.contributor.authorKeles, Erol
dc.contributor.authorAkyigit, Abdulvahap
dc.contributor.authorYalcin, Sinasi
dc.date.accessioned2026-08-12T17:36:23Z
dc.date.issued2022
dc.departmentFırat Üniversitesi
dc.description.abstractObjective: To determine prestin levels in patients with sensorineural hearing loss and to assess whether the prestin level could be a determining factor in predicting sensorineural hearing loss. Material and methods: The study was carried out with patients that presented to the Department of Otorhinolaryngology of Firat University. Patients were divided into four groups of 30 subjects. Group 1: individuals aged >= 55 years with no hearing loss (control group); Group 2: individuals aged 20 to 55 years with no hearing loss (control group); Group 3: individuals aged 20 to 55 years with sensorineural hearing loss; Group 4: individuals aged =55 years with presbycusis. Following an audiometry examination, 5 cc blood was taken from all patients to assess serum prestin levels. Results: Prestin levels were 445.32 pg/mL in Group 1; 452.79 pg/mL in Group 2; 123.64 pg/mL in Group 3; and 79.54 pg/mL in Group 4. No difference was found between the serum prestin levels of the younger patients with hearing loss (Group 3)] and of the patients with presbycusis (Group 4) (p=0.084). No difference was found between the serum prestin levels of the younger (Group 1) and the older (Group 2) patients with presbycusis (p=0.399). Significant differences (with higher levels in the control groups) were found in between the prestin levels of between Group 3 (the younger patients with sensorineural hearing loss) and Group 2 (younger controls), and between Group 4 (older patients with presbycusis) and Group 1 (older controls) (p <0.001 and p <0.001, respectively). Conclusion: Serum prestin levels can be used as biomarkers for assessing patients with presbycusis and sensorineural hearing loss. They can also be used together with audiometry tests to predict the patient's potential level of hearing loss. (C) 2021 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights reserved.
dc.description.sponsorship[TF.19.06]
dc.description.sponsorshipFunding This work was supported by the scientific investiga-tion project department of F?rat University Medical Fac-ulty. (Project No:TF.19.06)
dc.identifier.doi10.1016/j.anl.2021.09.010
dc.identifier.endpage373
dc.identifier.issn0385-8146
dc.identifier.issn1879-1476
dc.identifier.issue3
dc.identifier.pmid34732317
dc.identifier.scopus2-s2.0-85118772542
dc.identifier.scopusqualityQ2
dc.identifier.startpage368
dc.identifier.urihttps://doi.org/10.1016/j.anl.2021.09.010
dc.identifier.urihttps://hdl.handle.net/11508/57914
dc.identifier.volume49
dc.identifier.wosWOS:000806173200008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofAuris Nasus Larynx
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectPrestin
dc.subjectPresbycusis
dc.subjectHearing loss
dc.titleCan prestin level be a biomarker for determining sensorineural hearing loss?
dc.typeArticle

Dosyalar